Forte Biosciences (FBRX) Net Equity Issued and Repurchased (2016 - 2025)
Forte Biosciences (FBRX) posted quarterly Net Equity Issued and Repurchased of -$73.2 million for Q3 2025, down 915362.5% quarter-over-quarter from $8000.0 in Q1 2024.
Forte Biosciences (FBRX) Net Equity Issued and Repurchased (2016 - 2025) Analysis & Trends
Forte Biosciences (FBRX) has reported Net Equity Issued and Repurchased for 9 consecutive years, with -$73.2 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$73.2 million; the TTM figure through Dec 2025 stood at -$73.2 million (changed N/A YoY), while the FY2025 annual figure was $1.8 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased fell to -$73.2 million in Q3 2025 per FBRX's latest filing, from $8000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $25.0 million in Q1 2022 and bottomed at -$73.2 million in Q3 2025.
- Historically, Net Equity Issued and Repurchased has averaged -$1.1 million across 4 years, with a median of $7.7 million in 2022.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 221.9% in 2023 and fell as far as 99.98% in 2023.
- Forte Biosciences' Net Equity Issued and Repurchased stood at $7.7 million in 2022, then soared by 221.9% to $24.8 million in 2023, then sank by 99.97% to $8000.0 in 2024, then plunged by 915362.5% to -$73.2 million in 2025.
- Business Quant data shows FBRX's Net Equity Issued and Repurchased at -$73.2 million in Q3 2025, $8000.0 in Q1 2024, and $24.8 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -73.22 Mn |
| Sep 30, 2025 | -73.22 Mn |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Sep 30, 2023 | 24.79 Mn |
| Sep 30, 2023 | 24.79 Mn |
| Mar 31, 2023 | 6,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Dec 31, 2022 | 7.70 Mn |
| Dec 31, 2022 | 7.70 Mn |
| Sep 30, 2022 | 7.70 Mn |
| Sep 30, 2022 | 7.70 Mn |
| Mar 31, 2022 | 25.00 Mn |
| Mar 31, 2022 | 25.00 Mn |
| Dec 31, 2020 | 42.68 Mn |
| Dec 31, 2020 | 42.68 Mn |
| Jun 30, 2020 | 16.32 Mn |
| Jun 30, 2020 | 16.32 Mn |
| Mar 31, 2020 | 7.70 Mn |
| Mar 31, 2020 | 7.70 Mn |